REPRODIVAC - Next-generation vaccines and diagnostics to prevent livestock reproductive diseases of worldwide impact

家畜地方性和人兽共患的传染性生殖疾病在全球范围内造成重大经济损失，威胁粮食安全和公共卫生。REPRODIVAC将开发新的和改进的疫苗和诊断工具，以更好地控制四种优先的人工流产疾病：猪繁殖与呼吸综合征(PRRS)、Q热、绵羊地方性流产(OEA)和猪布鲁氏菌病。该财团横跨学术界和工业界，拥有互补的专业知识，包括结构生物学、微生物学、免疫学、植物和兽医科学。这使得我们能够用跨学科的方法来解决生殖障碍：(1)应用反向和结构疫苗学来选择和设计疫苗和诊断候选抗原；(2)利用相关的蛋白质表达系统来生产这些抗原；(3)生产合理的减毒和病毒载体疫苗；以及(4)开发一套分子和免疫诊断测试，包括区分接种疫苗和受感染动物(DIVA)的护理点测试(PoC)。我们将开发一种具有广泛保护性的PRRSV疫苗，并开发一种与PRRSV中和抗体滴度可靠相关的血清学ELISA法。我们将确定Q热的保护性亚单位疫苗候选者，并验证伴随的血清学DIVA测试。我们将进一步改进OEA疫苗以实现商业化，并寻求与DIVA兼容的下一代亚单位疫苗以及血清学和分子DIVA/POC测试的补充方法。我们将开发猪种布鲁氏菌减毒活疫苗和提高特异性的布鲁氏菌病诊断试验。我们的工业合作伙伴将进一步开发这些新的疫苗和诊断方法，并向用户提供。因此，通过使用疫苗和诊断开发方面的最新技术，REPRODIVAC将改善动物健康和福利、畜牧业的生产力和可持续性，以及人类健康。

Endemic and zoonotic infectious reproductive diseases of livestock cause major economic losses globally and threaten both food security and public health. REPRODIVAC will develop new and improved vaccines and diagnostic tools required to better control four priority abortifacient diseases: porcine reproductive and respiratory syndrome (PRRS), Q fever, ovine enzootic abortion (OEA), and porcine brucellosis. The consortium spans academia and industry with complementary expertise including structural biology, microbiology, immunology, plant and veterinary sciences. This enables us to address reproductive disorders with an interdisciplinary approach: (1) applying reverse and structural vaccinology to select and design vaccine and diagnostic candidate antigens; (2) exploiting relevant protein expression systems for the production of these antigens; (3) producing rationally attenuated and viral vectored vaccines; and (4) developing a suite of molecular and immunological diagnostic tests, including point-of-care tests (PoC) to discriminate vaccinated from infected animals (DIVA). We will develop a broadly protective PRRSV vaccine, and a serological ELISA that will reliably correlate with PRRSV neutralising antibody titres. We will identify protective subunit vaccine candidates for Q fever and validate a companion serological DIVA test. We will further refine an OEA vaccine for commercialisation and pursue a complementary approach towards a DIVA-compatible next-generation subunit vaccine and serological and molecular DIVA/PoC tests. We will develop live attenuated Brucella suis vaccines and brucellosis diagnostic tests with improved specificity. These new vaccines and diagnostics will be further developed by our industrial partners and made accessible to users. Thereby by using the latest technologies in vaccine and diagnostic development REPRODIVAC will improve animal health and welfare, productivity and sustainability of the livestock sector, as well as human health.